Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8931 for mild to moderate Alzheimer's disease
ACTRN12612000869875Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of verubecestat in Alzheimer's disease (AD) (4 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in ADAS-Cog score and Change from baseline in ADCS-ADL score. Started Dec 2012; status: terminated.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12612000869875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000869875.